Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07935317
PHASE2

A Study of Tersolisib (LY4064809) and Abemaciclib With Hormone Therapies in Participants With PIK3CA-Mutated Early Breast Cancer

Sponsor: Eli Lilly and Company

View on ClinicalTrials.gov

Summary

The main purpose of this study is to compare two ways of giving the anti-cancer medicines abemaciclib and hormone therapy with tersolisib in participants with early breast cancer that has a genetic mutation (PIK3CA mutation). For each participant, the study will last up to 56 weeks and include 12 visits.

Official title: A Phase 2, Open-label, Randomized Study Investigating the Tolerability of Concurrent Versus Staggered Administration of Abemaciclib and Endocrine Therapy With Tersolisib in Patients With HR+, HER2- Node-Positive, PIK3CA-Mutated Early Breast Cancer.

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

120

Start Date

2026-12

Completion Date

2028-01

Last Updated

2026-11-13

Healthy Volunteers

No

Interventions

DRUG

Abemaciclib

Administered orally

DRUG

Tersolisib

Administered orally

DRUG

Letrozole

Administered orally

DRUG

Anastrozole

Administered orally

DRUG

Exemestane

Administered orally

Locations (9)

Cancer and Blood Specialty Clinic

Los Alamitos, California, United States

USO - Rocky Mountain Cancer Centers

Lakewood, Colorado, United States

Winship Cancer Institute, Emory University

Atlanta, Georgia, United States

Dana-Farber Cancer Institute

Boston, Massachusetts, United States

Stefanie Spielman Comprehensive Breast Center

Columbus, Ohio, United States

Texas Oncology - West Texas

Amarillo, Texas, United States

Texas Oncology - Balcones

Austin, Texas, United States

South Texas Accelerated Research Therapeutics (START)

San Antonio, Texas, United States

USO - Virginia Cancer Specialists

Reston, Virginia, United States